Provides Compelling Rationale for the Upcoming Phase 2b Clinical Study in Patients with Poor Response to Androgen Receptor Signaling InhibitorsCALGARY,...
SOUTH SAN FRANCISCO, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal...
WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on...
The Company’s Reach has Grown to Over 317 Million in Just 14 Months and Monetization is Now UnderwayLOS ANGELES, CA,...
BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile...
VANCOUVER, British Columbia, June 24, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an...
BOULDER, Colo., June 24, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical...
Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s DiseaseMIAMI, June 24, 2021 (GLOBE...
SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing...
Retailer Extends Relationship with Inovalon to 2028BOWIE, Md., June 24, 2021 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider...
Orphazyme A/SCompany announcement No. 19/2021Company Registration No. 32266355 Copenhagen, Denmark, June 24, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a...
MISSISSAUGA, Ontario, June 24, 2021 (GLOBE NEWSWIRE) -- PRIMED Medical Products partnering with GlobalMedic and Traffic Tech to donate 38...
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on...
TORONTO, June 24, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the...
DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’),...
Phase 2 trial expected to begin in the first quarter of 2022BASEL, Switzerland, June 24, 2021 (GLOBE NEWSWIRE) -- VectivBio...
Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4...
4D-110: Initial clinical safety data at both of the two dose levels in the Phase 1 clinical trial indicate that...
EDEN PRAIRIE, Minn., June 24, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering...
Primary endpoint, change in DUX4-driven gene expression which was included as an experimental biomarker, was not metLosmapimod showed statistically significant*...